Effects of combined treatment with calcitriol plus alendronate on bone mass and bone turnover in postmenopausal osteoporosis: two years of continuous treatment | Health & Environmental Research Online (HERO)

Health & Environmental Research Online (HERO)

Print Feedback Export to File

This record has one attached file:

Citation
Tags

HERO ID

2751179

Reference Type

Journal Article

Title

Effects of combined treatment with calcitriol plus alendronate on bone mass and bone turnover in postmenopausal osteoporosis: two years of continuous treatment

Author(s)

Frediani, B; Allegri, A; Bisogno, S; Marcolongo, R

Year

1998

Is Peer Reviewed?

Yes

Journal

Clinical Drug Investigation
ISSN: 1173-2563

Report Number

IPA/99/1159115

Volume

Drug Invest

Issue

REF 47

Page Numbers

235-244

Language

English

Abstract

IPA COPYRIGHT: ASHP An open, randomized, placebo controlled study evaluating the efficacy of the combination of alendronic acid (alendronate) (10 mg/day) and calcitriol (0.5 mcg/day) on bone mass compared with alendronate or calcitriol monotherapy in 120 postmenopausal healthy women with osteoporosis, ages 45-75 yr, was conducted for 2 yr of continuous treatment; calcium (500 mg/day) was given to 30 patients as a placebo. Bone mineral density (BMD) appeared to be significantly higher in the group of patients receiving combined therapy compared with the group treated with alendronate or calcitriol alone. In the placebo group, BMD decreased significantly.